Oren Elmaliah - Chief Financial Officer | My Size (MYSZ) Executive Profile & Compensation

About Oren Elmaliah

Oren Elmaliah is Chief Financial Officer (CFO) of My Size, Inc. effective April 1, 2025, after serving as a director from May 2017 until stepping down on March 6, 2025 to assume the CFO role . He founded Accounting Team IL in September 2015 and has held finance roles including controller at Enlivex Therapeutics Ltd. (since February 2017) and CFO of Presstek Israel (since January 2017); prior roles include Financial Director at CFO Director Ltd. and Risk Management Consultant at RSM International Limited . Education: B.A. in Accounting/Economics and M.Sc. in Finance/Accounting from Tel Aviv University; licensed Certified Public Accountant in Israel . During his tenure, company TSR (value of initial $100 investment) was $157 for 2024 and $199 for 2023 per pay-versus-performance disclosure ; My Size revenues rose from $4.459M (FY22) to $6.996M (FY23) to $8.257M (FY24), while EBITDA improved from $(7.802)M (FY22) to $(5.098)M (FY23) to $(2.999)M (FY24)*. Values retrieved from S&P Global.

Past Roles

Organization	Role	Years	Strategic impact
Accounting Team IL	Founder, Account Manager	Since Sep 2015	Built a consultancy providing bookkeeping, controller and CFO services to public companies .
Enlivex Therapeutics Ltd.	Controller	Since Feb 2017	Led public company financial reporting controls .
Presstek Israel	Chief Financial Officer	Since Jan 2017	Oversaw finance operations .
LG Electronics Israel	Israel Authorities Reporting Officer	Since Sep 2015	Managed regulatory financial reporting interfaces .
Chiasma	Local Financial Report Consultant	Since Sep 2015	Supported local financial reporting .
CFO Director Ltd.	CPA, Financial Director	Jul 2011–Aug 2015	Directed finance projects and CPA work .
RSM International Limited	Risk Management Consultant	Jun 2010–Jul 2011	Advised on risk management frameworks .

External Roles

Organization	Role	Years	Strategic impact
My Size, Inc. (Board)	Director (Class I)	May 2017–Mar 2025	Audit Committee chair (2024); audit committee financial expert; 100% meeting attendance in 2024 .

Fixed Compensation

Component	Terms	Effective Date	Amount
CFO services agreement (Accounting Team Ltd., 100% owned by Elmaliah)	Bookkeeping, controller and CFO services	Mar 1, 2025 (agreement); CFO effective Apr 1, 2025	NIS 40,000/month (approx. $11,000) initially .
CFO services agreement (updated fee)	Same services	Current as of Jul 2025 Proxy	NIS 63,000/month (approx. $18,000) .

Company has standard executive employment agreements with notice periods, non-compete, confidentiality, and invention ownership arrangements; enforceability of non-competes may be limited under applicable law . Elmaliah’s CFO engagement is via a services company agreement rather than a direct employment contract .

Performance Compensation

Incentive type	Metric	Weighting	Target	Actual	Payout	Vesting
Director RSUs (non-employee director grant)	Service-based (vesting milestone)	N/A	N/A	N/A	N/A	2,500 RSUs granted Feb 14, 2024; vest Jan 1, 2025 .
Director Options	Service-based vesting tranches	N/A	N/A	N/A	N/A	150 options outstanding as of Nov 4, 2024; options were originally granted Oct 8, 2020 with director vesting schedules in 4 tranches (dates disclosed in option footnotes) .

No CFO-specific bonus targets, performance metrics, or equity grants disclosed for Elmaliah in 2025 filings reviewed .
RS/RSU acceleration: 2024 executive restricted stock grants (for CEO/CFO/COO) include accelerated vesting upon change in control; director RSUs vesting terms were time-based to Jan 1, 2025 .

Equity Ownership & Alignment

Holder	Beneficial ownership (shares)	% of outstanding	Composition	Notes
Oren Elmaliah	2,650	<1%	2,500 restricted stock; options to purchase up to 150 shares	As of July 8, 2025; percent based on 3,103,076 shares outstanding .

Insider trading policy prohibits short sales, options transactions, hedging or other speculative transactions in company stock; pre-clearance and blackout periods apply to covered persons .
Executive Clawback Policy adopted per Nasdaq Rule 10D-1; requires recoupment of erroneously awarded compensation after accounting restatements .
No pledging of shares disclosed; no stock ownership guideline disclosure found in reviewed proxies .

Employment Terms

Appointment and role: Elmaliah appointed CFO effective April 1, 2025; stepped down from board March 6, 2025 .
CFO engagement structure: Services agreement with Accounting Team Ltd. (100% owned by Elmaliah); initial NIS 40,000/month (approx. $11,000) effective March 1, 2025; updated fee NIS 63,000/month (approx. $18,000) as of proxy filing .
Severance/change-of-control economics: Not disclosed for Elmaliah’s CFO agreement in filings reviewed .
Indemnification: Company maintains indemnification agreements and D&O insurance for directors and executive officers .
Non-compete/confidentiality: Company-standard arrangements apply to executive officers; enforceability may be limited .

Board Governance (prior role)

Committees (2024): Audit (chair in 2024 proxy), Compensation, Nominating & Corporate Governance; identified as “audit committee financial expert” .
Attendance: Audit Committee met 4 times in 2024 with 100% attendance; Board met 15 times in 2024 with 100% attendance .
Proxy card designation: Named as proxy holder (with CEO) in 2025 Annual Meeting materials prior to CFO appointment .

Related Party Transactions

CFO services provided via Accounting Team Ltd., an entity 100% owned by Elmaliah; agreement terms and monthly fees disclosed .

Performance & Track Record

Metric	FY 2022	FY 2023	FY 2024
Revenue ($USD)	$4.459M*	$6.996M*	$8.257M*
EBITDA ($USD)	$(7.802)M*	$(5.098)M*	$(2.999)M*

*Values retrieved from S&P Global.

TSR (company-level per PVP table): Value of $100 initial investment at Dec 31: $199 (2023) and $157 (2024) .
2025 progress: Q3 2025 press release indicates sequential revenue growth to $2.6M, margin expansion, and net loss narrowed to $2.8M; Elmaliah listed as Investor Contact in IR .

Compensation Structure Analysis

Transition from director to CFO altered pay mix from modest cash+equity director compensation in 2024 to primarily fixed monthly services fees in 2025; no Elmaliah-specific annual bonus or equity grants disclosed post-appointment .
Option repricing: On June 4, 2025, the Compensation Committee repriced certain options to $1.28, including the CEO, former CFO, and COO; Elmaliah was not listed among repriced award holders, suggesting his 150 options retained prior terms .
Equity plan capacity expanded significantly (proposal to increase 2017 Plan reserve to 756,691 shares and adopt evergreen) implying potential future grants but no specific Elmaliah grant amounts disclosed .

Say-on-Pay & Peer Group

No advisory say-on-pay vote or compensation peer group disclosures were identified in the 2024/2025 proxies reviewed .

Expertise & Qualifications

Credentials: CPA (Israel); BA and MSc from Tel Aviv University; extensive finance and reporting roles across public companies .
Governance expertise: Designated audit committee financial expert .

Work History & Career Trajectory

Progression from risk management consulting (RSM) to finance leadership (CFO Director Ltd., Presstek Israel) and public company reporting (Enlivex), culminating in founding a finance services firm and appointment as public-company CFO .

Equity Ownership & Alignment Details

Category	Vested vs. Unvested	Exercisable vs. Unexercisable	In-the-money value	Pledged/Hedged
Restricted stock (2,500)	Vested Jan 1, 2025 per director grant schedule	N/A	Not disclosed	Hedging prohibited by policy; no pledging disclosed .
Options (150)	Fully vested by 2022 based on standard 2020 grant tranches; exact Elmaliah vesting not itemized	Exercisable (timing not itemized)	Not disclosed	No repricing disclosure for Elmaliah; anti-hedging policy applies .

Investment Implications

Alignment: CFO’s ownership is modest (<1%), with anti-hedging and clawback policies supporting alignment; lack of disclosed ownership guidelines and low personal stake may limit pay-for-performance alignment .
Retention risk: Engagement via a services company (rather than direct employment) with no disclosed severance/change-in-control terms could increase mobility risk; however, fee increase from NIS 40,000 to NIS 63,000 suggests retention-oriented adjustment .
Trading signals: No Form 4s found; option repricing excluded Elmaliah, avoiding a potential red flag; equity plan expansion indicates potential dilution but not specific to Elmaliah .
Execution: Company trends show revenue growth and improving EBITDA; CFO credibility is supported by prior public-company reporting experience; monitoring future disclosures on CFO incentives and grants is key to evaluating pay-performance coupling .

Note: Financial values in the Performance & Track Record table were retrieved from S&P Global.*

Citations: